A Trump executive order is pushing to tie what Medicare pays for certain prescription drugs to the lower prices that other wealthy countries pay for the same medicines. The idea, often called “most favored nation” pricing, is that the United States should not pay several times what Germany or Canada pays for an identical drug. It is a directive, not a finished policy — the order tells federal agencies to pursue the goal, and how far it actually reaches for patients depends on rulemaking and legal challenges still to come.
What the order actually directs
The executive order instructs the Department of Health and Human Services to work toward aligning U.S. drug payments with the lowest prices paid by comparable developed nations. As NBC News reported on the order, it sets a target rather than an immediate price cut, directing officials to develop mechanisms to move toward international reference pricing for certain drugs.
The word “seeks” matters. An executive order can set direction and press agencies to act, but changing what Medicare pays for drugs generally requires formal rulemaking, and in some cases new legal authority. A nonpartisan Congressional Research Service analysis of most-favored-nation drug pricing lays out the legal and practical questions such an approach raises, including how it would be implemented and whether it would survive court challenges — the same hurdles that slowed an earlier attempt at a similar policy.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
Why drug prices are so much higher here
The premise behind the order is a real and well-documented gap. The United States routinely pays far more for brand-name prescription drugs than other high-income countries, where governments negotiate prices directly or set them through national health systems. For Medicare beneficiaries, high list prices flow through to premiums, deductibles, and the amount owed at the pharmacy counter, especially for expensive specialty medications.
Recent law already moved in the direction of lower Medicare drug costs through separate channels — capping annual out-of-pocket drug spending and letting Medicare negotiate prices on a set of high-cost drugs. The executive order is a distinct and broader push, aimed at benchmarking prices to what other countries pay rather than negotiating drug by drug. Whether the two approaches reinforce each other or overlap is part of what agencies must sort out.
What it could mean for your pharmacy bill — eventually
For now, the order does not change what any beneficiary pays. There is no new price at the counter, no form to file, and no immediate savings to claim. If the policy is implemented and holds up, the potential benefit would be lower costs on affected drugs over time, but that outcome is uncertain and, at best, years away. The drug industry has strongly opposed international reference pricing and is likely to challenge any binding rule in court, which can delay or block implementation.
Beneficiaries who want to see what a policy like this might affect can review how their drugs are priced and covered now through the Medicare Plan Finder, which shows each plan’s cost for specific medications. That is the tool that reflects real, current prices, as opposed to a proposed change whose scope is still being decided.
How to read news like this
The useful stance is cautious interest, not budgeting around it. An executive order signals intent and can start a long process, but it is not a law and not a guaranteed price cut. Watch for actual rulemaking from HHS and CMS, which is where a directive becomes something a pharmacy honors, and expect legal fights along the way. In the meantime, the concrete levers a household can pull today — comparing drug plans during open enrollment, asking about generics and pharmacy assistance programs, and checking eligibility for Medicare’s Extra Help — remain the reliable ways to lower a real drug bill while the policy debate plays out.
Why an earlier version stalled — and what that suggests
This is not the first attempt to peg U.S. drug payments to foreign prices. A similar most-favored-nation effort in a previous term was blocked in court before it could take effect, largely on procedural grounds about how the rule was issued. That history is the best guide to what happens next: expect the drug industry to challenge any binding rule, expect litigation to slow implementation, and expect a gap of months or years between a directive and any change a patient would notice at the pharmacy. A policy that could reshape drug pricing is exactly the kind that opponents have the resources and incentive to fight at every step.
For beneficiaries, the sensible response is to separate the headline from your budget. Nothing about the order lowers a copay today, and building expectations around a savings that may never materialize invites disappointment — or worse, makes you a target for scams promising to “sign you up” for cheaper drugs. The concrete savings levers that exist right now are unglamorous but real: comparing Part D plans each open enrollment on the Medicare Plan Finder, asking your doctor about therapeutically equivalent generics, using manufacturer and pharmacy assistance programs, and checking whether you qualify for Extra Help. Those work regardless of how the most-favored-nation fight plays out.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
